[Perspectives] Cancer revolution: science, innovation, and hope A stone's throw from Dublin's Merrion Square, where medical luminaries such as William Stokes and William Wilde plied their craft, stands the airy Georgian structure of the St Stephen's Green Centre. Typically housing an assortment of boutiques and galleries, it is, until Oct 31, 2025, hosting something more unusual, Cancer Revolution: Science, Innovation and Hope, a major new exhibition by… The Lancet Oncology November 26, 2025 Original source
[Perspectives] Cancer and comedy: a review of three stand-up specials A cancer diagnosis does not leave much room for humour, but this year I saw three stand-up comedians who found plenty to talk about and took to the stage to share it with London audiences. The Lancet Oncology November 26, 2025 Original source
[News] Government shutdown and Medicare changes impact cancer care in the USA The effects of Medicare funding cuts and the longest ever shutdown of the US Federal Government have slowed momentum to a standstill in cancer prevention, screening, and treatment, warned the Association of American Cancer Institutes (AACI), which represents more than 100 academic and freestanding cancer centres in the USA and Canada. The Lancet Oncology November 26, 2025 Original source
[News] More e-cigarette users than cigarette smokers for the first time in the UK The number of adults using e-cigarettes or vapes has exceeded the number of cigarette smokers in the UK for the first time, according to figures released on Nov 4, 2025, from the Office for National Statistics. The Lancet Oncology November 26, 2025 Original source
[News] Europe's Beating Cancer Plan delayed by “legislative inaction” The success of Europe's Beating Cancer Plan (EBCP) is at risk of being undermined by slow progress on alcohol, tobacco, and nutrition control, according to an implementation findings study published on Oct 20, 2025. The Lancet Oncology November 26, 2025 Original source
[News] New Zealand extends breast cancer screening to 70–74-year-olds As of Oct 15, 2025, New Zealand has, begun a nationwide extension to its breast cancer screening programme, which will now include women aged 70–74 years as well as those already eligible (aged 45–69 years). This will mean tens of thousands more women will be able to access free mammograms once every 2 years, beginning with those aged 70 and… The Lancet Oncology November 26, 2025 Original source
[News] Eastern Mediterranean Region backs Cairo Call on breast cancer Health ministers in the Eastern Mediterranean region have officially adopted the Cairo Call to Action on Breast Cancer, uniting governments in the region behind a shared framework to address long-standing inequities in cancer care. The agreement outlines priorities to strengthen primary care screening, improve diagnostic and treatment services, expand psychosocial support, and integrate cancer data systems. The Lancet Oncology November 26, 2025 Original source
[News] ESMO Congress 2025 Sara A Hurvitz (Fred Hutch Cancer Center, Seattle, WA, USA) and colleagues presented results from the randomised, open-label, phase 3, VIKTORIA-1 trial in 392 patients with HR+/HER2- advanced breast cancer. Medium progression-free survival was 9·3 months in patients receiving the triplet combination of gedatolisib (180 mg, intravenous, once weekly for 3 weeks), fulvestrant (500 mg, intramuscular, every 2 weeks [cycle… The Lancet Oncology November 26, 2025 Original source
[Corrections] Correction to Lancet Oncol 2025; 26: 1443–53 Di Federico A, Stumpo S, Mantuano F, et al. Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis. Lancet Oncol 2025; 26: 1443–53—In figure 4A of this Article, the p value should have read p=0·20, and in figure… The Lancet Oncology November 26, 2025 Original source
[Corrections] Correction to Lancet Oncol 2024; 25: 1038–52 Allaf ME, Kim S-E, Master V, et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol 2024; 25: 1038–52—In this Article, some of the numbers of patients in the Results and figure 1 have been corrected. The appendix has also been corrected. These corrections have… The Lancet Oncology November 26, 2025 Original source
[Correspondence] Misclassification of p16-positive, HPV-negative patients biases de-escalation trials – Authors' reply We appreciate the important points raised by Jessica T Lovett and colleagues regarding p16 immunohistochemistry as a surrogate for HPV status in oropharyngeal squamous cell carcinoma in de-escalation studies such as MC1675.1 As they noted, the prognostic implications of p16 and HPV discordance have been previously analysed, such as in a multinational study by Mehanna and colleagues.2 Patients who were… The Lancet Oncology November 26, 2025 Original source
[Correspondence] Misclassification of p16-positive, HPV-negative patients biases de-escalation trials We read with interest the Article by Daniel Ma and colleagues in The Lancet Oncology.1 Ma and colleagues should be congratulated on completing a randomised trial of de-escalated radiotherapy in patients with p16-positive oropharyngeal squamous cell carcinoma. The authors report progression-free survival, local regional control, freedom from distant metastases, and overall survival as secondary endpoints. The de-escalation protocol resulted in… The Lancet Oncology November 26, 2025 Original source
[Correspondence] SBRT in oligometastatic castration-resistant prostate cancer The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy (SBRT) with androgen receptor pathway inhibitors (ARPIs) in oligometastatic castration-resistant prostate cancer (mCRPC). This study is the second randomised trial, after the ARTO trial,2 to evaluate this combination. Both PCS-9 and ARTO showed improved radiographical progression-free survival with SBRT. However, a significant… The Lancet Oncology November 26, 2025 Original source
[Correspondence] SunRISe-4 perioperative safety and TURBT stratification – Authors' reply We thank Wei Luo and colleagues for their insightful comments on our Article.1 We would like to offer some clarifications on the points raised. The Lancet Oncology November 26, 2025 Original source
[Correspondence] SunRISe-4 perioperative safety and TURBT stratification We read with great interest the interim analysis of the SunRISe-4 trial by Andrea Necchi and colleagues.1 This study assessed the efficacy and safety of neoadjuvant TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy.1 The authors reported a 42% pathological complete response rate with manageable toxicity, underscoring the potential to combine… The Lancet Oncology November 26, 2025 Original source
[Comment] The paradox of generics: broader access, less freedom The Italian National Health Service is founded on universal coverage and equal access to care.1 In this context, sustainability is not optional, but structural; innovative treatments must coexist with responsible use of constrained financial resources. In oncology, where novel therapies have improved outcomes but also driven up costs, generic drugs represent a crucial tool.2 When patent protection expires, bioequivalent formulations… The Lancet Oncology November 26, 2025 Original source
[Comment] A deliverable national cancer control plan for the UK: lessons from abroad and the need for discipline at home The UK has had serial national cancer control plans (NCCPs) since 1997. Early progress was undeniable, but momentum has waned over the past 15 years, with considerable slippage in cancer survival rankings (eg, the UK is ranked 28th of 33 countries, with similar wealth and income, for 5-year survival with lung and stomach cancer)1 and very poor performance in the… The Lancet Oncology November 26, 2025 Original source
[Comment] Re-establishing human-centred care In 2021, the Global Institute of Psychosocial, Palliative, and End-of-Life Care (University of Toronto, Canada) in collaboration with the Institute of Cancer Policy (King's College London, UK) launched a project called Biomedicine and the Soul of Medicine: Optimising the Balance. As part of this project, a multidisciplinary symposium held over 3 days on Palliative Care, Culture, and the Clinic brought… The Lancet Oncology November 26, 2025 Original source
[Comment] Targeting IDH mutation: another milestone, but not the finish line Targeted therapy has entered the stage of glioma management. Mutated isocitrate dehydrogenase (IDH) is the molecular hallmark of WHO grade 2 diffuse low-grade gliomas. In The Lancet Oncology, Timothy F Cloughesy and colleagues compared the mutated IDH inhibitor vorasidenib with placebo for diffuse low-grade gliomas without high-risk features, with 6 months' additional follow-up.1 As expected with the short additional follow-up,… The Lancet Oncology November 26, 2025 Original source
[Comment] Focused ultrasound treatments could increase survival in individuals with glioma Non-invasive and targeted transcranial focused ultrasound (FUS) treatments combined with systemically administered microbubbles enhance the delivered chemotherapeutic dose within brain tumours, due to reversible blood–brain barrier opening (BBBO).1–3 In preclinical studies, increased drug delivery has led to measurable overall survival benefit in animal models of high-grade glioma.4–7 However, to date, there has been no evidence of prolonged overall survival in… The Lancet Oncology November 26, 2025 Original source